Research groups
| Molecular Biology of Breast Cancer | Cancer genome variation |
|
|
| Headed by Group Leader and Professor Anne-Lise Børresen-Dale | Headed by Group Leader and Professor Vessela N. Kristensen |
Project groups
| Tumor initiating cells in breast cancer progression | Molecular signatures of disseminated tumor cells in breast cancer | Statistical integrated approaches | Response and Side Effects of Cancer Therapy | Molecular Profiling of GI Cancer |
|
|
|
|||
| Therese Sørlie | Lars O. Baumbusch | Hiroko K. Solvang | Hege Edvardsen | Elin H. Kure |
| Translational studies with a special focus on lung cancer | Cancer in the respiratory tract | Genomic and functional analysis of therapeutic targets in breast cancer | TP53 and somatic genetics of breast cancer | |
|
|
![]() |
|||
| Åslaug Helland | Odd Terje Brustugun |
Kristine Kleivi Sahlberg | Anita Langerød |
Our goal is to follow the linear time course of predisposition, initiation, early stages and advanced disease and to dissect the molecular mechanisms triggered at each stage and to follow the multidimentional interactions at various levels in a systems biology approach to be able to better do risk estimation, prognostication and prediction.
To reach these goals we have divided our research into 7 activities:
- Gene environment interaction in breast cancer risk
- Tumor initiation and early diagnosis
- Tumor progression and metastasis
- Prediction of treatment response and targeted therapy
- Integrated approaches
- Functional validation
- Biostatistical challenges and approaches
Contact information:
Department of Genetics, Institute for Cancer Research
The Norwegian Radium Hospital, N-0310 Oslo, Norway
Phone: +47 22 93 56 77, Fax: +47 22 93 44 40, Switchboard: +47 22 93 40 00
Research coordinator: Gry A. Geitvik
Department secretary: Mona Hagen
May 7, 2012
Latest publications
Dept of Genetics
Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing
PLoS One, 7 (4), e34150
PubMed 22529906
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Nature (in press)
PubMed 22522925
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
J Clin Oncol (in press)
PubMed 22473155














Print this page
